Candida Antibodies & Antigen Panel

IgG antibodies to Candida albicans develop following systemic or persistent mucosal exposure and represent a long-lived adaptive immune response. Most healthy adults carry detectable IgG titres from commensal colonisation of the gastrointestinal and genitourinary tracts. Elevated IgG may indicate chronic or recurrent infection, systemic candidiasis in immunocompromised hosts, or — more controversially in functional medicine contexts — persistent low-grade immune activation attributed to gut dysbiosis or intestinal permeability.

Candida IgG is used to assess exposure and immune memory but does not distinguish active infection from past exposure or asymptomatic colonisation. In immunocompromised patients elevated IgG combined with IgA or IgM supports a diagnosis of invasive or chronic candidiasis, while in integrative practice it is sometimes interpreted as a marker of prolonged antigen exposure, though this application lacks wide consensus.

IgA is the predominant immunoglobulin at mucosal surfaces and in secretions, where it binds and neutralises antigens without triggering inflammation. Elevated secretory and serum IgA to Candida can reflect active mucosal infection, recurrent vulvovaginal or oropharyngeal candidiasis, or chronic gut colonisation with immune activation. IgA responses are shorter-lived than IgG and more closely track active or recent mucosal challenge.

Candida IgA is a marker of mucosal immune engagement and is elevated in recurrent or persistent mucosal candidiasis. Some integrative clinicians interpret elevated IgA as evidence of intestinal candida overgrowth, though this hypothesis is not robustly validated. Absent IgA in a patient with recurrent infections may indicate selective IgA deficiency, which increases susceptibility to mucosal pathogens.

IgM is the first antibody class produced during a primary immune response and can also appear during reactivation or acute exacerbation of chronic infection. Candida IgM indicates recent or acute exposure and is particularly relevant in invasive candidiasis or disseminated infection, where it may rise before IgG. Persistent IgM can signal ongoing immune challenge or failure to clear the organism.

Elevated Candida IgM suggests acute or recent infection and is used alongside IgG and IgA to time the immune response. In immunocompromised patients IgM elevation prompts investigation for systemic candidiasis. Isolated IgM elevation in otherwise healthy individuals is less well characterised and may reflect transient mucosal breach or recent antibiotic use.

Candida antigen detection identifies fungal cell-wall components (such as mannan or beta-glucan) in serum or dried blood, indicating active fungal presence. Antigenaemia is uncommon in healthy individuals and is most often seen in invasive candidiasis, where it precedes or accompanies positive blood cultures. In the functional medicine literature circulating antigen is occasionally interpreted as evidence of intestinal translocation, though this is not a mainstream infectious-disease application.

A positive Candida antigen result points to active infection rather than immune memory and is a prompt for urgent evaluation in high-risk patients (neutropenia, immunosuppression, indwelling catheters). In otherwise well patients the clinical significance of detectable antigen on a dried blood spot panel is uncertain and should be correlated with symptoms, risk factors, and other markers before attributing systemic infection.